Tarsus Pharmaceuticals, Inc. TARS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -15.7%+50.2pp | -65.9%+755pp | -820.5%-578pp | -242.9%-222pp | |
| Net margin | -14.7%+48.4pp | -63.2%+716pp | -778.9%-538pp | -240.5%-216pp | |
| EBITDA margin | -15.3%+49.9pp | -65.2%+751pp | -815.8%-574pp | -241.7%-221pp | |
| Returns | |||||
| Return on equity | -23.4%+31.4pp | -54.8%+14.9pp | -69.7%-35.2pp | -34.5%-26.2pp | |
| Return on assets | -14.1%+21.8pp | -36%+19.1pp | -55.1%-24.6pp | -30.5%-22.6pp | |
| Return on invested capital | -32.3%+86.3pp | -118.6%+78.4pp | -197%— | —— | |
| Efficiency | |||||
| Asset turnover | 1×+0.4× | 0.6×+0.5× | 0.1×-0.1× | 0.1×-0.2× | |
| Liquidity | |||||
| Current ratio | 3.9×-0.6× | 4.4×-2.5× | 6.9×-7.7× | 14.6×-0.7× | |
| Quick ratio | 3.8×-0.6× | 4.4×-2.5× | 6.9×-7.7× | 14.6×-0.7× | |
| Cash ratio | 1.4×+0.2× | 1.2×-4.9× | 6.1×+1.4× | 4.6×-10.3× | |
| Leverage | |||||
| Debt-to-equity | 0.2×-0.1× | 0.3×+0.2× | 0.2×+0.1× | 0.1×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×+0.1× | |
| Interest coverage | -7.9×+7.4× | -15.4×+27.4× | -42.8×-14.1× | -28.7×+731× | |
| Per Share | |||||
| Book value per share | $8.22+37.7% | $5.97-10.9% | $6.70-14.4% | $7.84-3.4% | |
| Valuation | |||||
| Market capitalization | $3.48B+64.2% | $2.12B+227% | $646.87M+65.1% | $391.82M-15.7% | |
| Enterprise value | $3.37B+61.2% | $2.09B+361% | $453.66M+33.2% | $340.49M+15.6% | |
| Price / sales | 7.7×-3.9× | 11.6×-25.5× | 37.1×+21.9× | 15.2×+7.0× | |
| Price / book | 10.1×+0.7× | 9.4×+6.1× | 3.3×+1.3× | 2×-0.8× | |
| EV / sales | 7.5×-4.0× | 11.4×-14.6× | 26×+12.8× | 13.2×+8.0× | |
| Earnings yield | -1.9%+3.5pp | -5.5%+15.5pp | -21%-5.2pp | -15.8%-12.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Tarsus Pharmaceuticals, Inc. (TARS) runs a 42.7% gross margin and a -9.5% operating margin, with a -9.0% net margin.
- Where do Tarsus Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Tarsus Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
